Drug interactions
Obinutuzumab + Zoster vaccine recombinant
Severity: Minor
Obinutuzumab and Zoster vaccine recombinant: minor interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
The recombinant zoster vaccine is non-live and safe to give, but obinutuzumab B-cell depletion may reduce the antibody response. Protection may therefore be less than in untreated patients.
What this interaction means in plain words
Obinutuzumab and Zoster vaccine recombinant have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised.
Why it happens
B-cell depletion reduces antibody production in response to vaccine antigen.
What to do
Vaccinate ideally at least 2 to 4 weeks before obinutuzumab, but do not withhold the recombinant vaccine if already on therapy. Continue standard zoster vigilance.
What to ask your pharmacist
- Is there anything I should notice while taking both?
- Do I need to tell my doctor at the next visit?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Obinutuzumab and Zoster vaccine recombinant, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Obinutuzumab
Frequently asked questions
Can I take Obinutuzumab with Zoster vaccine recombinant?
MediHelp rates the interaction as minor. Obinutuzumab and Zoster vaccine recombinant have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised. The recombinant zoster vaccine is non-live and safe to give, but obinutuzumab B-cell depletion may reduce the antibody response. Protection may therefore be less than in untreated patients.
How serious is the interaction between Obinutuzumab and Zoster vaccine recombinant?
MediHelp rates it minor, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Vaccinate ideally at least 2 to 4 weeks before obinutuzumab, but do not withhold the recombinant vaccine if already on therapy. Continue standard zoster vigilance.
What other medicines interact with Obinutuzumab?
MediHelp also lists interactions of Obinutuzumab with, for example, Measles mumps and rubella vaccine, Adenovirus types 4 and 7 live, Axicabtagene ciloleucel. The full list is on the Obinutuzumab page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
